1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Delta Asia International Corporation

Delta Asia International Corporation

TTPEX:6762
147.00
TWD
-2.00
(-1.34%)
6.26BMarket Cap
Oct 26Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
5.63
10.27
5.37
12.27
16.82
17.28
12.55
13.77
15.74
18.81
- -
Basic EPS, GAAP
1.21
0.95
0.07
3.14
6
4.24
4.64
2.33
1.55
0.63
- -
Free Cash Flow per Basic Share
- -
- -
-0.75
3.45
6.51
1.97
-12.64
-29.29
-0.18
2.15
- -
Dividend per Share
- -
- -
0.06
0.06
2.24
5.4
1.75
0.7
0.14
0.25
- -
Book Value per Share
2.27
6.94
7.07
10.69
29.82
28.94
31.93
33.55
34.96
35.56
35.29
Tangible Book Value per Share
2.25
6.92
6.99
10.61
29.76
28.89
31.84
33.3
34.82
35.49
35.26
Basic Weighted Avg Shares
33
18
30
31
33
31
37
37
37
37
37
Sales/Revenue/Turnover
185
185
162
383
554
531
463
508
581
694
- -
Operating Margin (%)
26.24
13.29
-1.51
32.94
47.64
34.15
28.8
21.74
6.53
8.51
- -
Depreciation Expense
- -
- -
21
34
38
55
55
68
172
216
- -
Net Income, GAAP
40
17
2
98
198
130
171
86
57
23
- -
Effective Tax Rate (%)
19.92
15.14
- -
20.05
20.39
19.86
20.58
19.39
2.11
10.6
- -
Profit Margin (%)
21.53
9.29
1.36
25.57
35.68
24.51
37
16.89
9.85
3.38
- -
Working Capital
56
43
44
143
902
894
403
-17
-375
-383
-422
LT Debt
- -
- -
- -
69
432
410
484
1,147
725
601
486
Total Equity
74
228
232
351
1,100
1,068
1,178
1,238
1,290
1,313
1,303
Return on Invested Capital (%)
- -
12.95
- -
29.52
20.67
9.38
6.55
3.86
1.23
1.69
- -
Return on Capital (%)
- -
11.03
- -
30.14
20.26
8.99
11.14
4.21
2.48
1.53
- -
Return on Common Equity (%)
- -
11.38
0.96
33.65
27.27
12.02
15.26
7.1
4.53
1.8
- -

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
783
776
829
LT Borrowings
309
264
203
LT Finance Leases
292
288
283
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
37
37
37
Market Capitalization
6,507
5,504
6,261

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
513
491
536
Cash, Cash Equivalents & STI
171
149
178
Accounts Receivable, Net
116
110
132
Inventories
211
216
214
Total Current Liabilities
896
927
959
Payables & Accruals
- -
- -
- -
ST Debt
783
776
829
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
3.7%
1.82%
Free Cash Flow
- -
-438.71%
-1,284.59%
Net Income, GAAP
- -
-28.98%
-59.03%
Sales/Revenue/Turnover
- -
5.31%
19.58%
Total Cash Common Dividend
- -
0.2%
77%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
100
138
166
177
581
2025
164
195
- -
160
694
2026
136
207
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.07
0.53
0.13
0.96
1.55
2025
0.34
0.03
- -
-0.01
0.63
2026
-0.36
0.54
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.14
2025
- -
- -
- -
- -
0.25
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ya Wen Hsu
Full Time Employees
220
Sector
Health technology
Industry
Medical specialties
Address
No. 239, Nanshang Road Taoyuan TP Taiwan 338021
IPO Date
Dec 18, 2020
Website
deltaasia.com.tw
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Delta Asia International Corporation specializes in the manufacturing and development of medical devices and their components. Founded in 2004 and headquartered in Taoyuan City, Taiwan, the company provides a comprehensive range of services including medical device tooling design, mold development, injection molding, CNC machining, assembly, automation, and metrology. Its product portfolio encompasses parts and final products for cardiovascular minimally invasive surgical equipment, abdominal cavity minimally invasive surgical devices, disposable surgical robotic equipment, blood glucose monitors, automated insulin delivery systems, physiological monitoring devices, safety syringes, and orthopedic surgical instruments. Delta Asia serves global markets with a focus on the Americas and Asia. The company operates advanced cleanroom facilities and precision manufacturing systems, ensuring compliance with stringent quality standards such as ISO 13485, Taiwan GMP, and FDA 21 CFR 820 QSR. It manages complex supply chains and offers end-to-end project management from design feedback to mass production, emphasizing high efficiency, rapid design iteration, and superior product quality. Recent developments include continuous investment in automation technologies and maintaining close partnerships with multinational medical device companies to support innovative product pipelines. Delta Asia has also enhanced its production capabilities with robotic automation and temperature- and humidity-controlled production environments to ensure product safety and consistency. Delta Asia International Corporation remains a key player in the medical device OEM manufacturing sector, focusing on providing high-quality, precision-manufactured medical device parts and finished products while maintaining strong customer relationships and continually advancing its technical expertise in the medical device field. The company has seen revenue growth and maintains its competitive edge through technology investments and quality assurance enhancements in the past 1-2 years.